Valeant Pharma (VRX) & Salix Pharma to Stay Outstanding Litigation and Extend 30-Month Stay Regarding Actavis' ANDA for Xifaxan (Rifaximin)
Tweet Send to a Friend
Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
